3
Announcements
Trials
Browse
Landscape
Phase
Phase 4
1
Phase 3
1
Phase 2
1
Phase 1
1
Status
Terminated
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Genitourinary
1
Conditions
Prostatic Neoplasms
91
Neoplasm Metastasis
7
Prostatic Neoplasms, Castration-Resistant
5
Breast Neoplasms
3
Neoplasms
2
Castration-resistant Prostate Cancer
2
Urinary Bladder Neoplasms
1
Stage II Prostate Adenocarcinoma
1
Salivary Glands Tumors
1
Prostate Cancer Metastatic
1
Prostate Adenocarcinoma
1
Oligometastatic Prostate Carcinoma
1
Newly Diagnosed Oligometastatic Prostate Cancer
1
Neoadjuvant Therapy
1
NSCLC Harboring NRG1 Fusion
1
Metastatic Hormone-sensitive Prostate Cancer (mHSPC)
1
Metastatic Castration-resistant Prostate Cancer (mCRPC)
1
Metastatic Castration-Resistant Prostate Cancer
1
Metastatic Castration Resistant Prostate Cancer
1
Hyperaldosteronism
1
Cushing Syndrome
1
Carcinoma, Transitional Cell
1
Adrenocortical Carcinoma
1
Adenocarcinoma
1
Interventions
enzalutamide
4
cabazitaxel
3
Docetaxel
3
Prednisone
2
talazoparib
1
rucaparib
1
pembrolizumab
1
olaparib
1
Zuclomiphene
1
XRP6258
1
Standard of Care
1
Radiosurgery
1
Positron Emission Tomography Computed Tomography
1
LY3023414
1
Injections
1
Carboplatin
1
Abituzumab
1
Abiraterone Acetate
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 2
×
Prostate Cancer Metastatic
×
Abiraterone Acetate
×
Clear all
NCT02379390
2019-06-21
PRIMCAB
Sanofi
Phase 2
Terminated
8 enrolled
8 charts